An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

Clinical trial NCT03088111 · UNKNOWN

Trial details

NCT number: NCT03088111
Sponsor: Elusys Therapeutics
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Infection, Bacterial Anthrax

Start date: 2023-12-01
Primary completion: 2023-12-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.